Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$39.19 USD
+0.73 (1.90%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $39.21 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$39.19 USD
+0.73 (1.90%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $39.21 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
On Ionis' (IONS) second-quarter 2018 conference call, investor focus will remain on the company's progress with the pipeline candidates as well as royalty revenues earned from Spinraza.
Biogen (BIIB) Q2 Earnings & Sales Beat Estimates, Shares Up
by Zacks Equity Research
Biogen (BIIB) beats estimates on both counts in the second quarter. The company's multiple sclerosis drugs' sales up sequentially amid competition.
Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates
by Zacks Equity Research
It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Regulus Stock Plunges on Cash Concerns Despite Restructuring
by Zacks Equity Research
Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.
Pfizer's Tafamadis Gets Breakthrough Therapy Designation
by Zacks Equity Research
Pfizer's (PFE) rare disease candidate, tafamidis, gets Breakthrough Therapy designation in the United States for the treatment of transthyretin cardiomyopathy.
Ionis (IONS) Beats Earnings & Misses Revenues in Q1
by Zacks Equity Research
Ionis Pharmaceutical (IONS) reported positive quarter with earnings beating estimates while revenues missing the same.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.
Ionis Pharmaceuticals (IONS) in Focus: Stock Moves 5.8% Higher
by Zacks Equity Research
Shares of Ionis Pharmaceuticals (IONS) rose 5.8% on Friday.
Ionis (IONS) Clinches Licensing Agreement with AstraZeneca
by Zacks Equity Research
Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.
Alnylam Falls on Pfizer's Rare Disease Drug Success
by Zacks Equity Research
Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.
Pfizer's Rare Disease Candidate Meets Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.
Biogen to Buy Mid-Stage Neuropsychiatry Asset From Pfizer
by Zacks Equity Research
Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).
Ionis (IONS) Beats Both Earnings & Revenues in Q4
by Zacks Equity Research
Ionis Pharmaceutical (IONS) reported positive quarter with earnings and revenues beating estimates.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.
Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.
Biogen Halts Tysabri Development in Stroke as Study Fails
by Zacks Equity Research
Biogen's Tysabri (natalizumab) falters in a phase IIb study, evaluating it for acute ischemic stroke (AIS) indication.
Implied Volatility Surging for Ionis Pharmaceuticals (IONS) Stock Options
by Zacks Equity Research
Surging implied volatility makes Ionis Pharmaceuticals (IONS) stock lucrative to the option traders.
Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies
by Zacks Equity Research
Biogen (BIIB) expands collaboration with Ionis to identify new drug candidates for the treatment of SMA.
Ionis (IONS) Beats on Q3 Earnings, Revenues Miss
by Indrajit Bandyopadhyay
Ionis Pharmaceutical (IONS) reported mixed quarter with earnings beating estimates while revenues missing it.
Should You Buy Ionis (IONS) Ahead of Earnings?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earned $50 million in milestone payments from Biogen. Spinraza had a strong third quarter as announced by Biogen in its earnings results.
4 Scorching Hot Momentum Stocks to Beat the Market
by Zacks Equity Research
This screen will help you to get into momentum stocks that are storming ahead. Highlighted stocks include: IONS, OSB and SKX.
BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer
by Zacks Equity Research
BioLineRx (BLRX) and partner Genentech initiate a phase Ib/II study to evaluate the company's lead pipeline candidate, BL-8040, in combination with Tecentriq for treating gastric cancer.